Moderna is the second company after Pfizer to receive emergency approval on Saturday for its coronavirus disease (Covid-19) vaccine. Pfizer’s vaccine is approved in the UK, Canada, Mexico and Bahrain, among others. Russia has approved two domestic vaccines for early use, while China has approved four of its vaccines, two of which have also been approved in the United Arab Emirates and one in Bahrain.
The year started with WHO Wuhan health officials reporting a mysterious cluster of pneumonia cases in 27 people on December 31, 2019, followed by scientists in China who isolated the new coronavirus (Sars-CoV-2) and itss on January 7 shared genetic sequence on January 11th.
In a matter of days, scientists began using a range of technologies to develop vaccines, and today there are two approved vaccines, six with early or restricted approval, 18 in advanced studies, and at least 60 in early stages.
Moderna and Pfizer-BioNTech used the messenger RNA (mRNA) technology never used before, while Oxford, Sputnik V, Biotech and Janssen and China’s CanSino used defective adenoviruses to fight Sars-CoV-2, the virus that causes Covid, used -19, while other developers such as Bharat Biotech in Hyderabad and Sinovac, Sinopharm-Wuhan and Sinopharm-Beijing in China are working with inactivated viruses.
Even with a drop in new Covid-19 cases last week, India topped the 10 million mark. All hopes are now on vaccines, which the government will deploy to 250 million most vulnerable people by summer 2021. Five experimental vaccines are in advanced clinical trials in India. The Serum Institute of India (SII) has filed for emergency approval for the Oxford-AstraZeneca vaccine, of which it is the world’s largest manufacturer, and Bharat Biotech in Hyderabad is preparing its trial data for late-stage approval.
India plans to bolster its piggyback on its universal vaccination program, which vaccinates the needs of more than 26 million newborns and 29 million pregnant women each year, to begin vaccinating priority groups that include health and frontline workers, followed by individuals from 50 years. subject to early availability.
NITI Aayog member Dr. VK Paul said on Saturday that a dozen nations have asked India for vaccines, which is the world’s largest manufacturer of vaccines.
Aside from bilateral agreements, Pune-based SII is offering 200 million doses – with options for up to 900 million more doses – of the candidates AstraZeneca / Oxford or Novavax to Covax, a coalition for Epidemic Preparedness Innovation (CEPI) to ensure a global initiative fair access to Covid-19 vaccines for all countries regardless of income.
Covax announced on Friday that it had signed a pre-sale agreement with AstraZeneca for 170 million doses of the Oxford-AstraZeneca vaccine and a Memorandum of Understanding (MoU) with Johnson & Johnson for 500 million doses of the Janssen candidate, which is a single dose Vaccine. These contracts complement Covax’s existing 200 million doses contract with SII and another 200 million doses agreement for the Sanofi / GSK vaccine.
These upfront agreements will provide at least 1.3 billion donor-funded doses of approved vaccines to 92 low- and middle-income economies in early 2021. First deliveries are expected to begin vaccinating health care workers and frontline workers in 92 countries in mid-year, depending on regulatory approvals and countries’ readiness to deliver, with a target of up to 20% population coverage by the end of 2021 Year. Additional doses for higher coverage will be available in 2022.
As part of Covax’s research and development portfolio, Cepi has invested in 10 experimental vaccines, seven of which are in clinical trials and nine are in development. Cepi is currently reviewing additional candidates for assistance, including a next-generation experimental vaccine to increase options and availability.
With the arsenal of vaccines, the world can win the war on Covid-19, but this will only be possible if we do not remove masks or give up our vigilance until everyone is vaccinated.